US commercial architecture for CEOs and principals at Geneva-headquartered firms running a US subsidiary, a US trading desk, US clinical or commercial pathways, or direct outbound. Genevois discretion, Romandie engineering rigour, and multi-decade relationship discipline carried into a register the American buyer reads in twenty seconds.
The US clinical site is open, or the US trading desk is staffed, or the first US enterprise contract has been signed and the second is in process. The Genevois commercial materials, the home-market website, the deck, the principal's public presence, all of it is built on the local register that has carried the firm in Romandie and across European institutional readers for years. The American buyer scans it and finds nothing to engage with. The discretion that reads as competence in Geneva reads as commercial absence in Boston, in Cambridge, in San Diego, in Houston.
The Genevois register runs on reserve, multilingual fluency, multi-decade-relationship discipline, and Quai du Mont-Blanc institutional weight that is felt rather than declared. The American filter does not read felt weight. The American filter reads category anchor first, US outcome second, US peer set third. After those three, the institutional weight and the multi-decade discipline carry a great deal. Before those three, they are background noise the buyer scrolls past.
For commodity-trading-adjacent operators the problem is sharper. Cargill, Mercuria, Trafigura, Vitol, and Glencore have material US trading desks and US procurement readers, but the commodity-merchant identity reads as opaque to a US enterprise reader outside the trading function. The work is to position the non-trading commercial surfaces, the industrial assets, the supply contracts, the US enterprise services, with a US category claim that the American buyer can place independently of the trading-desk register.
The Genevois substance is real. The discretion is appropriate at home. The US-facing surface needs a parallel voice that the American buyer can read in twenty seconds. House view on Geneva operator entry into the US
The company is not the problem. The leader is not the problem. The US-facing frame is, and the frame is fixable.
Six to ten weeks. Single US category, single corridor. The firm rebuilds positioning, pricing posture, messaging, and trust architecture for the American buyer, then launches it into market. Common first engagement when one US-facing surface needs the register correction.
See the Sprint →Three to six months. Multi-channel US rebuild and run. Paid, owned, earned, conversion architecture, and sales enablement. The standard shape for Geneva operators committed to US scale across multiple non-trading commercial surfaces or clinical and commercial pathways.
See the Build →Monthly retainer, twelve-month minimum. Ongoing rebuild-and-run across multiple US-facing surfaces. Typical for Geneva operators running several US business lines, multiple US clinical sites, or post-acquisition integration of a US brand.
See the Partnership →No legal services. No SA, Sarl, or US entity formation. No L-1, E-2, EB-5, or O-1 visa work. No US tax structuring, FATCA analysis, or Switzerland-US tax-treaty review. No US banking introductions. No fiduciary services. No FINMA navigation, no Quai du Mont-Blanc regulatory work, no asset-management licensing, no fund-services authorisation work. No regulatory licensing, FDA submissions, or US securities work. No IP filing. No contract drafting. No US recruiting or executive search. No M&A advisory. No commodity-trading counsel, no US CFTC registration, no sanctions navigation.
These belong with Swiss counsel who specialise in US entry, with US counsel on the American side, with regulatory consultants who handle FDA and FINMA pathways, with FINRA and SEC counsel for asset-management work, and with sanctions and trading specialists where commodity activity touches US regulation. The firm works inside the parameters they set. When a marketing decision carries legal, tax, regulatory, or sanctions implications, the firm flags it and defers before execution.
The Genevois commercial register is reserved, multilingual, multi-decade-relationship-honest, and discreet by professional discipline. The home market reads it as competence and seriousness. The US enterprise reader reads it as commercial absence and as the firm having no US-facing identity to engage with. The work is to carry a second voice for US-facing surfaces and conversations, with the same substance underneath, in language the American buyer can place. The home-market voice keeps its discretion in full. The US-facing site, deck, outbound, follow-up cadence, and principal LinkedIn lead with the US category, the US outcome, and the US peer set.
Geneva commodity-trading houses including Cargill, Mercuria, Trafigura, Vitol, and Glencore have material US trading desks and US procurement readers, but the commodity-merchant identity reads as opaque to a US enterprise reader outside the trading function. The work is to position the operator's non-trading commercial surfaces, including industrial assets, supply contracts, US enterprise services, and any consumer-facing or institutional adjacency, with a US category claim that the American buyer can place independently of the trading-desk register. The trading-desk identity stays where it belongs and is not the front-page asset.
Geneva biotech and life sciences, medtech and devices including the Romande pharma and Geneva-Vaudois medtech cluster, commodity-trading-adjacent commercial operators where the marketing surface sits outside the trading desk, Quai du Mont-Blanc independent asset managers and fund-services adjacencies, Romandie engineering-commercial firms in instrumentation and precision engineering, and CERN-spinout deep-tech operators. Fit is confirmed in discovery, not in published sector lists.
CERN-spinout operators arrive with extraordinary technical depth and a science-led founder register that has carried European institutional readers and grant-bodies. The US enterprise procurement reader, or the US strategic partner, filters first on US category position, US peer set, and a commercial outcome claim. The rebuild keeps the science-led founder register in full for technical and academic conversations and constructs a parallel US-commercial register for partnership, procurement, and US institutional readers.
With an inquiry through the contact form and a short discovery conversation. The firm runs three engagements: Market Entry Sprint (6 to 10 weeks), Cross-Border Build (3 to 6 months), or Group Partnership (monthly retainer, 12-month minimum). Fit and pricing are confirmed in discovery, not published. Geneva operator engagements often begin as a Sprint when one US-facing surface needs the register correction, and as a Build when multi-channel US commercial architecture is the scope.
The wider Geneva entry gate for principals, operators, and family offices moving into the United States.
See the Geneva gate →How Geneva and Romandie life-science operators run the US clinical and commercial pathway translation.
Read the article →Three engagement shapes: Market Entry Sprint, Cross-Border Build, Group Partnership. Selection is by scope, not by sector.
See engagements →